Tudorza Pressair



Indications and Reactions:

Role Indications Reactions
Primary
Chronic Obstructive Pulmonary Disease 67.8%
Emphysema 7.5%
Asthma 3.4%
Dyspnoea 3.4%
Hypertension 3.4%
Bronchitis Chronic 2.7%
Anxiety 1.4%
Blood Cholesterol Increased 1.4%
Hypothyroidism 1.4%
Bronchitis 0.7%
Crohn's Disease 0.7%
Depression 0.7%
Diabetes Mellitus 0.7%
Dizziness 0.7%
Dysphonia 0.7%
Gastrooesophageal Reflux Disease 0.7%
Heart Rate Increased 0.7%
Inhalation Therapy 0.7%
Osteopenia 0.7%
Pulmonary Sarcoidosis 0.7%
Vision Blurred 12.7%
Off Label Use 10.1%
Dyspnoea 8.9%
Drug Ineffective 6.3%
Urinary Retention 6.3%
Death 5.1%
Headache 5.1%
Medication Error 5.1%
Product Taste Abnormal 5.1%
Cough 3.8%
Myalgia 3.8%
Nausea 3.8%
Oedema Peripheral 3.8%
Rash 3.8%
Weight Increased 3.8%
Blood Pressure Increased 2.5%
Chest Discomfort 2.5%
Diarrhoea 2.5%
Dysuria 2.5%
Loss Of Consciousness 2.5%
Secondary
Chronic Obstructive Pulmonary Disease 48.4%
Emphysema 19.4%
Bronchitis Chronic 12.9%
Dyspnoea 6.5%
Anxiety 3.2%
Chronic Myeloid Leukaemia 3.2%
Crohn's Disease 3.2%
Dizziness 3.2%
Convulsion 16.7%
Diarrhoea 8.3%
Myalgia 8.3%
Pruritus 8.3%
Sinus Congestion 8.3%
Urinary Retention 8.3%
Urine Flow Decreased 8.3%
Vaginal Odour 8.3%
Ventricular Tachycardia 8.3%
Vision Blurred 8.3%
Vomiting 8.3%
Concomitant
Chronic Obstructive Pulmonary Disease 39.3%
Product Used For Unknown Indication 16.1%
Hypertension 5.4%
Multiple Sclerosis 5.4%
Blood Pressure Abnormal 3.6%
Dyspnoea 3.6%
Emphysema 3.6%
Gastrooesophageal Reflux Disease 3.6%
Pain 3.6%
Asthma 1.8%
Atrial Fibrillation 1.8%
Bronchiolitis 1.8%
Depression 1.8%
Diabetes Mellitus 1.8%
Hypertonic Bladder 1.8%
Myelofibrosis 1.8%
Neuralgia 1.8%
Smoking Cessation Therapy 1.8%
Dyspnoea 14.3%
Chronic Obstructive Pulmonary Disease 7.1%
Drug Ineffective 7.1%
Homicidal Ideation 7.1%
Neoplasm Malignant 7.1%
Noninfective Bronchitis 7.1%
Off Label Use 7.1%
Pneumonia 7.1%
Prescribed Overdose 7.1%
Rib Fracture 7.1%
Sensory Loss 7.1%
Unevaluable Event 7.1%
Vomiting 7.1%